Alkermes plc Presents Positive Results from Phase 2 Clinical Study of ALKS 5461 in Major Depressive Disorder at 53rd Annual NCDEU Meeting
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Alkermes plc (NASDAQ: ALKS) today announced the presentation of positive phase 2 data for ALKS 5461, a novel opioid modulator, in patients with major depressive disorder (MDD) and inadequate response to standard therapies. In the phase 2 study, ALKS 5461 met its primary endpoint, met key secondary endpoints and demonstrated significant reduction in depressive symptoms versus placebo.
Help employers find you! Check out all the jobs and post your resume.
Alkermes plc (NASDAQ: ALKS) today announced the presentation of positive phase 2 data for ALKS 5461, a novel opioid modulator, in patients with major depressive disorder (MDD) and inadequate response to standard therapies. In the phase 2 study, ALKS 5461 met its primary endpoint, met key secondary endpoints and demonstrated significant reduction in depressive symptoms versus placebo.
Help employers find you! Check out all the jobs and post your resume.